Analysts Offer Insights on Healthcare Companies: Immune Design (NASDAQ: IMDZ) and Adamas Pharmaceuticals (NASDAQ: ADMS)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immune Design (IMDZResearch Report) and Adamas Pharmaceuticals (ADMSResearch Report) with bullish sentiments.

Immune Design (IMDZ)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Immune Design today and set a price target of $7.75. The company’s shares closed on Friday at $1.54, close to its 52-week low of $1.10.

Pantginis wrote:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential contribution from pipeline development. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -20.5% and a 23.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

Immune Design has an analyst consensus of Moderate Buy, with a price target consensus of $7.75.

See today’s analyst top recommended stocks >>

Adamas Pharmaceuticals (ADMS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Adamas Pharmaceuticals today and set a price target of $40. The company’s shares closed on Friday at $9.22, close to its 52-week low of $7.42.

Selvaraju observed:

“Valuation methodology, risks and uncertainties. Our valuation ascribes a $1.15B valuation to GOCOVRI in PD $400M value for ADS-5102 based on a risk-adjusted net present value (rNPV) using a 15% discount rate, 30% effective tax rate and 30% cost of sales and marketing. We utilize a 60% probability of success for ADS-5102.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -15.7% and a 25.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Adamas Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $25.25, implying a 173.9% upside from current levels. In a report issued on January 7, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.